Quick Answer
TriSalus Life Sciences, Inc. reported Net Income Loss of -$39.23 million for the year ending 2025.
- TriSalus Life Sciences, Inc. showed a decrease of -30.6% in Net Income Loss from 2024 to 2025.
- This data is from TriSalus Life Sciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: -$1.0 thousand | Q4 2020: -$711.4 thousand | Q1 2021: -$372.0 thousand | Q2 2021: $378.9 thousand | Q3 2021: $1.86 million | Q1 2022: -$7.87 million | Q2 2022: -$8.68 million | Q3 2022: -$8.09 million | Q1 2023: -$8.31 million | Q2 2023: -$13.99 million | Q3 2023: -$1.43 million | Q1 2024: -$13.21 million | Q2 2024: -$4.33 million | Q3 2024: -$2.40 million | Q1 2025: -$10.38 million | Q2 2025: -$8.29 million | Q3 2025: -$10.81 million.
- Over the full 5 years of available data (2021 to 2025), TriSalus Life Sciences, Inc.'s Net Income Loss has declined by 922.8%.
- Historical annual values: Fiscal year 2025: -$39.23 million | Fiscal year 2024: -$30.05 million | Fiscal year 2023: -$59.36 million | Fiscal year 2022: -$47.19 million | Fiscal year 2021: $4.77 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: